Intérêt de la tomographie par émission de positons au ( 18 F)-fluorodésoxyglucose pour la planification de la radiothérapie des cancers de l’œsophage localement évolués ou inopérables

Inter-Observer and Intra-Observer Variability in Gross Tumor Volume Delineation of Primary Esophageal Carcinomas Based on Different Combinations of Diagnostic Multimodal Images

Background and Purpose

This study aimed to investigate inter-/intra-observer delineation variability in GTVs of primary esophageal carcinomas (ECs) based on planning CT with reference to different combinations of diagnostic multimodal images from endoscopy/EUS, esophagography and FDG-PET/CT.

Materials and Methods

Fifty patients with pathologically proven thoracic EC who underwent diagnostic multimodal images before concurrent chemoradiotherapy were enrolled. Five radiation oncologist independently delineated the GTVs based on planning CT only (GTV_C), CT combined with endoscopy/EUS (GTV_CE), CT combined with endoscopy/EUS and esophagography (X-ray) (GTV_CEX), and CT combined with endoscopy/EUS, esophagography, and FDG-PET/CT (GTV_CEXP). The intra-/inter-observer variability in the volume, longitudinal length, generalized CI (CI_gen), and position of the GTVs were assessed.

Results

The intra-/inter-observer variability in the volume and longitudinal length of the GTVs showed no significant differences (p>0.05). The mean intra-observer CI_gen values for all observers was 0.73 ± 0.15. The mean inter-observer CI_gen values for the four multimodal image combinations was 0.67 ± 0.11. The inter-observer CI_gen for the four combined images was the largest, showing significant differences with those for the other three combinations. The intra-observer CI_gen among different observers and inter-observer CI_gen among different combinations of multimodal images showed significant differences (p<0.001). The intra-observer CI_gen for the senior radiotherapists was larger than that for the junior radiotherapists (p<0.001).

Conclusion

For radiation oncologists with advanced medical imaging training and clinical experience, using diagnostic multimodal images from endoscopy/EUS, esophagography, and FDG-PET/CT could reduce the intra-/inter-observer variability and increase the accuracy of target delineation in primary esophageal carcinomas.

Impact of positron emission tomography with computed tomography for image-guided radiotherapy

Therapeutic effectiveness in radiotherapy is partly related to correct staging of the disease and then precise therapeutic targeting. Positron emission tomography (PET) allows the stage of many cancers to be determined and therefore is essential before deciding on radiation treatment. The definition of the therapeutic target is essential to obtain correct tumour control and limit side effects. The part of adaptive radiotherapy remains to be defined, but PET by its functional nature makes it possible to define the prognosis of many cancers and to consider radiotherapy adapted to the initial response allowing an increase over the entire metabolic volume, or targeted at a subvolume at risk per dose painting, or with a decrease in the dose in case of good response at interim assessment.

PET imaging in adaptive radiotherapy of gastrointestinal tumors

INTRODUCTION

Radiotherapy is a cornerstone in the multimodality treatment of several gastrointestinal (GI) tumors. Positron-emission tomography (PET) has an established role in the diagnosis, response assessment and (re-)staging of these tumors. Nevertheless, the value of PET in adaptive radiotherapy remains unclear. This review focuses on the role of PET in adaptive radiotherapy, i.e. during the treatment course and in the delineation process.

EVIDENCE ACQUISITION

The MEDLINE database was searched for the terms ("Radiotherapy"[Mesh] AND "Positron-Emission Tomography"[Mesh] AND one of the site-specific keywords, yielding a total of 1710 articles. After abstract selection, 27 papers were identified for esophageal neoplasms, 1 for gastric neoplasms, 9 for pancreatic neoplasms, 6 for liver neoplasms, 1 for biliary tract neoplasms, none for colonic neoplasms, 15 for rectal neoplasms and 12 for anus neoplasms.

EVIDENCE SYNTHESIS

The use of PET for truly adaptive radiotherapy during treatment for GI tumors has barely been investigated, in contrast to the potential of the PET-defined metabolic tumor volume for optimization of the target volume. The optimized target definition seems useful for treatment individualization such as focal boosting strategies in esophageal, pancreatic and anorectal cancer. Nevertheless, for all GI tumors, further investigation is needed.

CONCLUSIONS

In general, too little data are available to conclude on the role of PET imaging during radiotherapy for ART strategies in GI cancer. On the other hand, based on the available evidence, the use of biological imaging for target volume adaptation seems promising and could pave the road towards individualized treatment strategies.